Turning Point Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for Combination of Elzovantinib and Aumolertinib in EGFR Mutant Met-Amplified Non-small Cell Lung Cancer

Turning Point Therapeutics, Inc. announced that the company has received clearance from the FDA for the company’s Investigational New Drug application for the combination of elzovantinib and aumolertinib in EGFR mutant MET-amplified advanced non-small cell lung cancer.